HIGH-VOLUME PCEA VERSUS PIEB FOR LABOUR ANALGESIA: A RANDOMISED, DOUBLE-BLIND, TWO-CENTER, NON-INFERIORITY STUDY IN NULLIPAROUS WOMEN INVESTIGATING QUALITY OF PAIN RELIEF

1N Filetici*, 2E Roofthooft, 3S Rex, 4CA Wong, 3M Van de Velde. 1Fondazione Polyclinico Universitario Agostino Gemelli IRCCS, Rome, Italy; 2Dept. Anesthesiology, GZA Ziekenhuizen, Antwerp, Belgium; 3Dept. Anesthesiology, UZ Leuven, Leuven, Belgium; 4Dept. Anesthesia, University of Iowa, Iowa City, USA

10.1136/rapm-2022-ESRA.81

Background and Aims Maintenance of neuraxial labour analgesia using programmed intermittent epidural boluses (PIEB) is superior compared to continuous epidural infusions with/without patient controlled epidural analgesia (PCEA), causing less breakthrough pain, motor block and local anesthetic (LA) consumption1. Compared to low-volume PCEA without background infusion, PIEB produces less breakthrough pain and motor block, despite higher LA consumption.

The goal of this randomised, double-blind, non-inferiority study was to investigate if high-volume PCEA without background infusion compared to PIEB+PCEA, set with equal boluses, results in a similar incidence of breakthrough pain and LA consumption.

Methods Following ethics approval and written consent, combined spinal-epidural for labour was performed in 360 nulliparous women. Analgesia was maintained with ropivacaine 0.12% and sufentanil 0.75 mcg/mL. Patients randomly received high-volume PCEA without background infusion set at 10 mL bolus with a 30 min lock-out or PIEB as 10 mL bolus every hour plus PCEA boluses of 5 mL with a 30 min lock-out. Breakthrough pain, motor block and LA consumption were recorded.

Results Final analysis was performed in 336 women (PCEA n=170; PIEB-PCEA n=166). Breakthrough pain occurred in 11.2% in the PCEA-group and 10.8% in the PIEB-group. Total LA consumption was lower in the PCEA-group than in the PIEB-group (mean 53.1 versus 65.2 mL respectively, p<0.0001). Motor block was not different between groups (p=0.783).

Conclusions High-volume PCEA without background infusion and PIEB showed a similar incidence of breakthrough pain and motor block. The PCEA-group had a lower total LA consumption.

EVALUATION OF PLASMA BUPIVACAINE LEVELS AT DIFFERENT TIME POINTS AFTER LOW THORACIC ERECTOR SPINAES PLANE BLOCK: AN OBSERVATIONAL PHARMACOKINETIC STUDY

1ZG Oztunal, 2O Selvi, 3O Senturk, 1MS Kapakli, 4H Aygun, 1U Deveci, 5S Tulgar*, 1Z Ozer. 1Maltepe University, Istanbul, Turkey; 2Cambridge University, Addenbrooke’s Hospital, London, UK; 3Cigli training and research hospital, Izmir, Turkey; 4Samsun University, Faculty of Medicine, Samsun, Turkey

10.1136/rapm-2022-ESRA.82

Background and Aims Erector Spinae Plane Block (ESPB) can be applied at all vertebral levels and low thoracic applications are reported in abdominal surgeries. To our knowledge there exists no study of the pharmacokinetics of different local anesthetics in low thoracic ESPB. Here, we aimed to measure and determine the time-concentration relation of the plasma bupivacaine levels at different time points after low thoracic ESPB.

Methods The observational pharmacokinetic study was performed between March 2021 and March 2022 after IRB approval. ASA class I-II patients aged between 18–65 y undergoing laparoscopic Nissen fundoplication were enrolled into the study. Patients who had paraspinal surgery or a history of previous abdominal surgery were excluded. At the end of the surgery, under general anesthesia, 20 mL of 0.25% bupivacaine was used consecutively to perform bilateral USG-guided ESPB at T9 level, using the out-of-plane technique. Blood samples were taken prior to ESPB and at 5th, 10th, 20th, 30th, 45th, 60th, 90th, 120th, 240th and 720th minutes after ESPB. Plasma bupivacaine concentration was measured using enzyme-linked immunosorbent assay (ELISA).

Results 12 male and 5 female patients with mean age of 39.35±14.93 y were included. Peak mean plasma bupivacaine concentration was observed at 30m (0.022±0.010 mcg/mL). The highest concentration was 0.041 mcg/mL at 60m, in one case. There was no difference in any of the measurements between men and women (p>0.05).

Conclusions Twenty mL of 0.25% bupivacaine for ESPB at the lower thoracic level offers safe pharmacokinetics.